Budget for Med Tech evaluation significantly increased in Spain

07

Oct 2021

On September 10, 2021, it was announced that the Government of Spain had increased the budget allocated to the Spanish Network of Agencies for the Evaluation of Health Technologies and Benefits (RedETS) by 48.2% (compared to last year) for the development of the annual work plan. This commitment to strengthen the evaluation of health technologies and decision-making based on the best available scientific evidence has resulted in the additional endowment of two million euros for the eight agencies that make up the RedETS.

In total, the 2021 budget for the evaluation of health technologies in the National Health System (SNS) amounts to €6,149,510. The distribution of this budget among the evaluation agencies is proportional to the workload assigned to each agency or evaluation unit according to its experience, resources, and the weighted percentage attributed to each activity.

The evaluation agencies that comprise RedETS and their respective budgets for 2021 are as follows:

  • Health Sciences Institute in Aragon (IACS) - €924,000
  • Evaluation and Planning Unit – Directorate of the Canary Islands Health Service (SESCS) - €892,500
  • Andalusian Health Technology Assessment Department (AETSA) - €887,000
  • Galician Agency for Health Technology Assessment (AVALIA-T) - €854,000
  • Health Institute Carlos III (ISCIII) - €824,510
  • Agency for Health Quality and Assessment of Catalonia (AQuAS) - €728,000
  • Basque Office for Health Technology Assessment (OSTEBA) - €724,500
  • Agency for Training, Research and Health Studies of the Community of Madrid Pedro Laín Entralgo (UETS-MADRID) - €315,000

As a consequence of the budget increase, the RedETS 2021 Work Plan has included three new lines of evaluation: non-pharmacological measures in the context of the COVID19 pandemic, digital services in health, and personalized medicine.

The RedETS evaluates the available scientific evidence and provides rigorous and quality information for better decision-making in the field of inclusion, use and/or exclusion of health technologies in the SNS. In Spain, for the inclusion of new health benefits and technologies in the Common Package of Benefits of the SNS, an evaluation report carried out by the RedETS is mandatory for an informed and cost-effective decision making in terms of the efficacy, safety, efficiency, and health utility.

The full details in Spanish can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts” and “Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

15

Oct 2021

The Scottish Health Technologies Group (SHTG) is a national health technology assessment (HTA) agency providing advice to NHSScotland on the use of new and existing health technologies, likely to have a significant impact on healthcare. In the third quarter of 2021, SHTG published only one report in relation to HeartFlow fractional flow reserve computerized tomography (FFRCT). Currently, the SHTG is working on assessments of technologies in the field of diabetes, digital health, surgical procedures, and other topics.

Read more

13

Oct 2021

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in September 2021. In total, 58 recommendations for registration, modification of registration conditions, and removal of devices from the List of reimbursable products and services (LPPR) were published. Opinions concern cardiovascular, orthopedic, peripheral vascular, and other groups of devices, as well as medical aids.

Read more

12

Oct 2021

On September 30, 2021, the 2020/21 National Tariff Payment System was published in England, and it came into effect on October 01, 2021. The publication has been delayed due to the COVID-19 pandemic.

Read more

11

Oct 2021

On September 20, 2021, Swedish Medical Technologies Product (MTP) Council announced ongoing horizon scanning for medical technology products used in obstructive lung diseases within the Orderly introduction framework. The Dental and Pharmaceutical Benefits Agency (TLV) initiated a theme survey, accepting suggestions until October 15, 2021.

Read more

08

Oct 2021

In September 2021, the National Institute for Health and Care Excellence (NICE) published three new Interventional Procedure Guidance (transapical transcatheter mitral valve-in-valve implantation for a failed surgically implanted mitral valve bioprosthesis, transapical transcatheter mitral valve-in-ring (TMVIR) after failed annuloplasty for mitral valve repair, and lateral elbow resurfacing for arthritis), and two new Medtech Innovation Briefings (Carnation Ambulatory Monitor, OrganOx metra for liver transplant). Also, one clinical guideline was updated.

Read more